Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
03.07.2026 13:46
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
03.07.2026 09:25
Bristol-Myers Squibb Companyâs growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1â26. Read more on BMY stock here.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
01.07.2026 13:11
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
01.07.2026 13:00
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb (BMY) Moves From Russell Growth Indexes To Value And Defensive
01.07.2026 01:07
Bristol-Myers Squibb (NYSE:BMY) has been added to the Russell 1000 Value Defensive and Russell 1000 Defensive Indexes. At the same time, the company has been removed from several growth-focused Russell benchmarks. This reclassification marks a shift in how major indexes group Bristol-Myers Squibb within the market. Bristol-Myers Squibb, a large US-based pharmaceutical company, now sits firmly in the value and defensive camp within the Russell index family. For investors who follow NYSE:BMY,...
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?
30.06.2026 13:07
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential […]
Beeline Medicines Announces Upsized Series A of $426.3 Million to Advance Category-Leading Autoimmune and Inflammatory Disease Portfolio
30.06.2026 11:00
– $126.3 million of new funding adds to previously announced $300 million Series A financing – – Proceeds will support advancement of afimetoran into pivotal development for lupus and clinical study initiations for multiple development candidates over the next 12 months – STAMFORD, Conn. and BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Beeline Medicines Corporation, a clinical-stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the live
Beeline ups its Series A round for immune drug work
30.06.2026 10:22
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial
30.06.2026 10:09
Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update and see upcoming catalysts.
3 Unpopular Stocks with Questionable Fundamentals
30.06.2026 09:37
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
AbbVie Stock's Growth Story Has One Question Mark
26.06.2026 16:03
The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
26.06.2026 15:50
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes
26.06.2026 11:00
Bristol-Myers Squibb offers a 4.7% dividend yield with strong profitability and value. The stock scores well on dividend and valuation ratings despite high payout ratio concerns.
Does Bristol Myers Squibb’s 2026 Dividend and Pipeline Ambition Reframe Its Capital Priorities (BMY)?
24.06.2026 02:09
Bristol Myers Squibb’s board previously declared a quarterly dividend of US$0.63 per share on its common stock, payable on August 3, 2026, to shareholders of record as of July 2, 2026. This dividend decision comes as the company works to address upcoming patent expirations by advancing a broad pipeline that includes 50 compounds and multiple new medicines targeted for launch by 2030. We’ll now examine how this affirmed dividend, alongside Bristol Myers Squibb’s expanding pipeline, shapes the...
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies
23.06.2026 19:37
Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks. On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous […]
How Kardigan spun deal leftovers into a $400M IPO
23.06.2026 10:21
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.
Merck Stock’s New Drugs Were Already Answering The Big Question
22.06.2026 14:46
While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.
1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
22.06.2026 13:07
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
The Nasdaq 100 Has Tripled Since 2020, But These 10 Mega-Caps Are Still Underwater
19.06.2026 13:43
The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who's still underwater and why?
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
19.06.2026 13:10
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.